- In November 2024, Electra Therapeutics announced that it received orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for ELA026, an innovative antibody therapy aimed at treating hemophagocytic lymphohistiocytosis (HLH). This designation is granted to encourage the development of treatments for rare diseases, providing benefits such as market exclusivity, tax incentives, and assistance in the regulatory process. The recognition of ELA026 as an orphan drug highlights its potential to address a significant unmet medical need in the HLH patient population, paving the way for further clinical development and eventual access to this promising therapy
- On December 10, 2022, the American Society of Hematology reported findings from a Phase II study in which patients received dexamethasone alongside ruxolitinib (15 mg twice daily) for an eight-week duration. Ruxolitinib, an orally administered Janus kinase (JAK) inhibitor, targets JAK enzymes and the downstream cytokines involved in haemophagocytic lymphohistiocytosis (HLH). While certain cytokines activated by the JAK pathway may induce glucocorticoid resistance, in vitro and in vivo studies suggest that ruxolitinib could potentially counteract this effect, and researchers noted that the medication was well tolerated, with no patients requiring dose adjustments
Frequently Asked Questions
The market is segmented based on Global Haemophagocytic Lymphohistiocytosis Treatment Market Segmentation, By Type (Familial and Acquired), Therapy Type (Immunotherapy, Chemotherapy, Targeted Therapy, and Others), Treatment (Medication and Surgery), Drugs (Emapalumab, Alemtuzumab, Infliximab, and Others), Route of Administration (Oral and Parenteral), End Users (Hospitals, Homecare, Specialty Clinics, Oncologist, Immunologist, and Others) – Industry Trends and Forecast to 2031
.
The Global Hemophagocytic Lymphohistiocytosis Treatment Market size was valued at USD 2.23 USD Billion in 2023.
The Global Hemophagocytic Lymphohistiocytosis Treatment Market is projected to grow at a CAGR of 5.14% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
